Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Medical Oncology
•
Myeloma
•
Hematology
What is your preferred regimen for a patient with newly diagnosed high-risk MM, transplant-eligible, with pre-existing grade 1 peripheral neuropathy?
Related Questions
How would you approach choosing a regimen for a patient with multiple myeloma refractory to daratumumab and lenalidomide, with severe neuropathy from bortezomib?
How do you approach post-transplant maintenance for patients with high-risk myeloma?
How is monoclonal gammopathy of renal significance (MGRS) different from myeloma kidney?
With the recent approvals of CAR-T for second-line therapy in myeloma, does this change your approach to use of consolidative autologous transplant or autologous transplant as second line therapy?
How would you approach a patient with solitary plasmacytoma with an FLC ratio >100, but a negative bone marrow biopsy and negative PET-CT?
What post-auto maintenance therapy do you recommend for patients with high-risk multiple myeloma?
Does the presence of osteoporosis change the extent of workup that should be performed for an older patient with otherwise serologically low-risk MGUS?
How do you modify Daratumumab-RVD relative to the protocols used in trials when used as a first-line agent to transplant-eligible patients with myeloma?
What induction regimen do you choose for high risk newly diagnosed multiple myeloma in light of the recent high risk focused studies?
What are alternative myeloma therapies for patients who are unable to afford lenalidomide or oral cyclophosphamide due to gaps in prescription drug coverage?
